New drug targets hepatitis b inside the liver – small study begins

NCT ID NCT06154278

Recruiting now Disease control Sponsor: University of Maryland, Baltimore Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This pilot study tests a drug called Imdusiran (AB-729) in 10 people with chronic hepatitis B. Participants receive four injections over 24 weeks and undergo two liver biopsies to measure how the drug works inside the liver and how it affects the virus. The goal is to understand the drug's action and its potential to control the infection.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Imdusiran (AB-729)
What this could lead to: If successful, this could point toward a way to control or reduce hepatitis B virus activity in the liver, potentially lowering the need for lifelong medication.
What could go wrong: This is a very small pilot study with only 10 participants, so results may not apply to everyone. It is also early-stage, and the drug may not work as hoped or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC HEPATITIS B are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic hepatitis B virus infection hepatitis B virus infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC HEPATITIS B

Contacts and locations

Locations

Institute of Human Virology, University of Maryland School of Medicine
RECRUITING

Baltimore, Maryland, 21201, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.